- Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimensKimmie Ng
Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Dana 1220, Boston, MA 02215, USA
Clin Cancer Res 19:3987-95. 2013..Everolimus, an oral inhibitor of mTOR, showed efficacy in patients with metastatic colorectal cancers in phase I studies...
- Prospective study of predictors of vitamin D status and survival in patients with colorectal cancerK Ng
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Br J Cancer 101:916-23. 2009....
- Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studiesY Bao
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
Br J Cancer 102:1422-7. 2010..Studies evaluating vitamin D status in relation to pancreatic cancer risk have yielded inconsistent results...